Core Insights - BeOne Medicines Ltd. (NASDAQ:ONC) is highlighted as a top biotech stock to consider for investment, with Barclays initiating coverage and rating it Overweight, setting a price target of $385 for the shares [1] Group 1: Anticipated Data Readouts - The first key catalyst for BeOne is the upcoming data on its BTK inhibitor for first-line mantle cell lymphoma, expected in the latter half of 2025 [2] - Additionally, data for BeOne's PD1 inhibitor combined with anti-HER2 for first-line gastroesophageal cancer is anticipated in the fourth quarter of 2025 [2] Group 2: Significance of Pivotal Data - A crucial driver for BeOne's growth is the topline pivotal data for zanidatamab, with or without tislelizumab, in first-line gastroesophageal adenocarcinoma [3] - BeOne Medicines Ltd. specializes in oncology treatments, focusing on blood cancers and solid tumors [3]